Affiliation:
1. Division of Hepatology Mount Sinai Kravis Children's Hospital New York New York USA
2. Division of Gastroenterology, Hepatology and Nutrition Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
3. Division of Pediatric Nephrology Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
4. Department of Quality Improvement, Pediatric Transplant Center Boston Children's Hospital Boston Massachusetts USA
5. Institutional Centers for Clinical and Translational Research Boston Children's Hospital, Harvard Medical School Boston Massachusetts USA
6. Division of Gastroenterology, Hepatology and Nutrition Yale New Haven Children's Hospital New Haven Connecticut USA
Abstract
AbstractBackgroundChronic kidney disease (CKD) impacts long‐term morbidity in pediatric liver transplant (LT) recipients. The prevalence of estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m2 (eGFR < 90) at our institution was 25% at 1 year post‐LT; thus, quality improvement (QI) project was initiated, aiming to decrease the prevalence of eGFR < 90 by at least 20% at 1 year‐post LT.MethodsChildren post‐LT under 19 years from 2010 to 2018 were included. Three QI interventions were implemented starting 1/2016: documentation of blood pressure percentile (BP%) and eGFR, documentation of a kidney management plan if either was abnormal, and amlodipine initiation prior to hospital discharge after LT. We compared the prevalence of eGFR < 90 at 3, 12, and 24 months after LT in the pre‐ and post‐intervention period.Results68 patients in pre‐ and 42 in post‐intervention periods met inclusion criteria. Pre‐intervention BP%, eGFR, and kidney management plan were documented at 25%, 10%, and 22%, compared to 71%, 83%, and 71% post‐intervention, respectively. 22% of patients were started on amlodipine prior to discharge from LT in the pre‐ versus 74% in the post‐intervention period. Prevalence of eGFR < 90 at 3 m post‐LT was 19% in pre‐ versus 14% in the post‐intervention period (p = .31); at 12 months 24% versus 7% (p = .01) and at 24 months 16% versus 6% (p = .13), respectively. Significant non‐modifiable risk factors for eGFR < 90 were malignancy (RR = 4.5, p < .0001), metabolic disorder (RR = 2.6, p = .02), and age at transplant (7% increased risk per year of age, p = .007).ConclusionBy improving documentation of BP%, eGFR, and kidney management plan, the prevalence of eGFR < 90 was decreased by a relative 74% and 60% at 12 and 24 months post‐LT, respectively.
Subject
Transplantation,Pediatrics, Perinatology and Child Health